Artificial Intelligence (AI) is revolutionizing drug repurposing by harnessing its abilities to analyze vast amounts of data, predict drug interactions and side effects, and identify synergistic drug combinations. This technology accelerates the discovery of new applications for existing drugs, potentially shortening the time and reducing costs associated with bringing treatments to market. While there are challenges, such as data quality and ethical concerns, successful AI-driven repurposing cases exist, including the identification of existing medications for treating COVID-19 and glioblastoma. As AI tools and regulatory processes evolve, the role of AI in drug repurposing is poised for significant expansion, promising a more efficient and personalized future for medicine.